Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704431 · ClinicalTrials.gov registry record · Phase 1
A Study With Darapladib to Collect Tolerability Information
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00704431: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT00704431 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00704431, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and the remaining 9 days of dosing will occur at home. Subjects will record any adverse events throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days after the last dose of darapladib for a follow-up visit. The total study duration for each subject including the screening, treatment and follow-up periods will be approximately 4 weeks.
Interventions
- DRUG SB-480848 (darapladib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
What the finished NCT00704431 record still lists
NCT00704431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which SB-480848 (darapladib) is the first listed.
NCT00704431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00704431 about?
NCT00704431 is a clinical study titled "A Study With Darapladib to Collect Tolerability Information". Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and the remaining 9 days of dosing will occur at home. Subjects will record any adverse events throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days after the last dose of da...
What is the current status of trial NCT00704431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00704431?
The interventions under investigation include: SB-480848 (darapladib) (DRUG).
Who is sponsoring clinical trial NCT00704431?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00704431's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia